(Q42681262)

4 November 2017

Comparison of goserelin and leuprolide in combined androgen blockade therapy (English)

1 reference

4 November 2017

1 reference

Sarosdy MF

1

1 reference

4 November 2017

Schellhammer PF

2

1 reference

4 November 2017

Sharifi R

3

1 reference

4 November 2017

Block NL

4

1 reference

4 November 2017

Soloway MS

5

1 reference

4 November 2017

Venner PM

6

1 reference

4 November 2017

Patterson AL

7

1 reference

4 November 2017

Vogelzang NJ

8

1 reference

4 November 2017

Chodak GW

9

1 reference

4 November 2017

Klein EA

10

1 reference

4 November 2017

Schellenger JJ

11

1 reference

4 November 2017

Kolvenbag GJ

12

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

4 November 2017

1 reference

4 November 2017

52

1 reference

4 November 2017

1

1 reference

4 November 2017

82-88

1 reference

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Phase III Randomised Study of Zoladex versus Stilboestrol in the Treatment of Advanced Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Patients' choice of treatment in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Advanced prostate cancer. Endocrine therapies and palliative measures

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900145-9

7 January 2021

10.1016/S0090-4295(98)00145-9

Identifiers

DOI

1 reference

4 November 2017

1 reference